Heinz Dürk

3.4k total citations · 1 hit paper
30 papers, 1.7k citations indexed

About

Heinz Dürk is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Heinz Dürk has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Rheumatology. Recurrent topics in Heinz Dürk's work include Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Heinz Dürk is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Heinz Dürk collaborates with scholars based in Germany, United States and United Kingdom. Heinz Dürk's co-authors include Mathias Rummel, Ulrich von Grünhagen, Dieter Hoelzer, Dorothea Kofahl-Krause, Wolfram Brugger, Ulrich Kaiser, Christina Balser, Christoph Losem, Martina Stauch and Juergen Barth and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Heinz Dürk

28 papers receiving 1.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 962 citations Mathias Rummel, N. Niederle et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heinz Dürk Germany	14	1.3k	991	767	275	213	30	1.7k
Michael Fridrik Austria	21	857 0.7×	898 0.9×	371 0.5×	290 1.1×	187 0.9×	83	1.8k
H Tilly France	16	1.3k 1.0×	856 0.9×	674 0.9×	183 0.7×	350 1.6×	44	2.0k
Tiemo Katzenberger Germany	29	1.8k 1.5×	1.2k 1.2×	889 1.2×	263 1.0×	354 1.7×	54	2.5k
B. Audhuy France	20	492 0.4×	986 1.0×	375 0.5×	316 1.1×	99 0.5×	48	1.9k
Eliza A. Hawkes Australia	20	1.0k 0.8×	847 0.9×	382 0.5×	230 0.8×	364 1.7×	133	1.6k
M J O'Connell United States	22	571 0.5×	1.4k 1.4×	324 0.4×	567 2.1×	109 0.5×	46	2.2k
B.Y. Yeap United States	20	595 0.5×	805 0.8×	295 0.4×	1.0k 3.7×	227 1.1×	65	2.0k
Glen R. Justice United States	15	679 0.5×	584 0.6×	480 0.6×	89 0.3×	148 0.7×	31	1.3k
Tara Baetz Canada	20	514 0.4×	904 0.9×	261 0.3×	391 1.4×	155 0.7×	71	1.5k
Rudolf Schlag Germany	16	669 0.5×	1.0k 1.0×	808 1.1×	137 0.5×	90 0.4×	60	2.3k

Countries citing papers authored by Heinz Dürk

Since Specialization

Citations

This map shows the geographic impact of Heinz Dürk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heinz Dürk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heinz Dürk more than expected).

Fields of papers citing papers by Heinz Dürk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heinz Dürk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heinz Dürk. The network helps show where Heinz Dürk may publish in the future.

Co-authorship network of co-authors of Heinz Dürk

This figure shows the co-authorship network connecting the top 25 collaborators of Heinz Dürk. A scholar is included among the top collaborators of Heinz Dürk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heinz Dürk. Heinz Dürk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Straka, Christian, Hans Salwender, Stefan Knop, et al.. (2021). Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. European Journal Of Haematology. 107(5). 529–542. 4 indexed citations

Straka, Christian, Martin Vogel, Martin Kropff, et al.. (2015). Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology. 33(15_suppl). 8511–8511. 7 indexed citations

Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. The Lancet. 381(9873). 1203–1210. 962 indexed citations breakdown →

Brunnberg, Uta, Michael Möhr, Richard Noppeney, et al.. (2011). Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Annals of Oncology. 23(4). 990–996. 31 indexed citations

Kötter, Ina, et al.. (2008). Morbus Behçet: Epidemiologie, Verlauf, therapeutische Optionen. DMW - Deutsche Medizinische Wochenschrift. 121(12). 382–388.

Neumann, J., et al.. (2008). Panzytopenie bei niedrig dosierter oraler Methotrexat-Therapie der Arthritis psoriatica. DMW - Deutsche Medizinische Wochenschrift. 114(34). 1286–1288.

Laack, Eckart, Andreas Krüll, Walburga Engel-Riedel, et al.. (2007). A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). Lung Cancer. 57(2). 181–186. 3 indexed citations

Dürk, Heinz. (2006). Maintenance Therapy for Multiple Myeloma with Particular Emphasis on Thalidomide. Oncology Research and Treatment. 29(12). 582–590. 2 indexed citations

Rummel, Mathias, S. Al-Batran, Manfred Welslau, et al.. (2005). Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 23(15). 3383–3389. 332 indexed citations

10.

Laack, Eckart, Birte Andritzky, Heinz Dürk, et al.. (2005). Docetaxel and Cisplatin as First-Line Treatment for Patients with Metastatic Esophageal Cancer: A Pilot Study. Oncology Research and Treatment. 28(12). 647–650. 18 indexed citations

11.

Laack, Eckart, Thomas Müller, Alexander Knuth, et al.. (2004). Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group. Journal of Clinical Oncology. 22(12). 2348–2356. 71 indexed citations

12.

Laack, Eckart, Thorsten Mende, Heinz Dürk, et al.. (2002). Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer. European Journal of Cancer. 38(5). 654–660. 7 indexed citations

13.

Laack, Eckart, Thorsten Mende, A. Chemaissani, et al.. (2001). Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer. European Journal of Cancer. 37(5). 583–590. 27 indexed citations

14.

Kötter, Ina, Heinz Dürk, & J. G. Saal. (1995). Sacroiliitis in sarcoidosis: Case reports and review of the literature. Clinical Rheumatology. 14(6). 695–700. 17 indexed citations

15.

Glück, T., et al.. (1995). [Cryoglobulinemia in chronic hepatitis C. Improvement by alpha-interferon is independent of virus elimination].. PubMed. 90(12). 674–80. 2 indexed citations

16.

Zierhut, Manfred, et al.. (1995). Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients.. PubMed. 4(4). 246–51. 21 indexed citations

17.

Schick, Fritz, Stephan H. Duda, Heinz Dürk, et al.. (1994). Eosinophilia-myalgia syndrome: Findings at MR imaging and proton spectroscopy of the lower leg. Magnetic Resonance Imaging. 12(3). 513–522. 10 indexed citations

18.

Frank, Hartmut, et al.. (1987). Fatty acids in liver microsomal lipids of rats exposed to hypoxia, tetrachloromathane, or both. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 922(1). 54–61. 3 indexed citations

19.

Dürk, Heinz & Hartmut Frank. (1984). Carbon tetrachloride metabolism in vivo and exhalation of volatile alkanes: Dependence upon oxygen partial pressure. Toxicology. 30(3). 249–257. 17 indexed citations

20.

Dürk, Heinz, et al.. (1984). Binding of trichloromethyl radicals to lipids of the hepatic endoplasmic reticulum during tetrachloromethane metabolism. Biochemical Journal. 223(3). 577–586. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact